Who Buys Osimertinib from India — 50 Importers Behind a $1.1M Market
India's osimertinib import market is served by 50 active buyers who collectively imported $1.1M across 130 shipments. INDIRA GANDHI MEMORIAL HOSPITAL (MALDIVES) leads with a 12.0% market share, followed by TO THE CONCERN PERSON and INCEPTA PHARMACEUTICALS LTD. The top 5 buyers together control 31.6% of total import value, reflecting a moderately competitive buyer landscape.
Osimertinib buyer data — 50 importers · $1.1M market · 130 shipmentsTransData Nexus · Indian Customs Data
Top Osimertinib Importers — Ranked by Import Value
INDIRA GANDHI MEMORIAL HOSPITAL (MALDIVES) is the leading osimertinib importer from India, holding a 12.0% share of the $1.1M market across 130 shipments from 50 buyers. The top 5 buyers — INDIRA GANDHI MEMORIAL HOSPITAL (MALDIVES), TO THE CONCERN PERSON (BRAZIL), INCEPTA PHARMACEUTICALS LTD (BANGLADESH), CONCERN PERSON WANILDA DE (BRAZIL), TO THE (BRAZIL) — collectively control 31.6% of total import value.
Top Osimertinib Buyers & Importers
Ranked by import value · 50 active buyers · Indian Customs (DGFT) data
Mar 2026
Top Osimertinib Buyers & Importers — Ranked by Import Value. 50 active buyers with import value, shipments, country and supplier data compiled from Indian Customs records by TransData Nexus.
Which companies are buying Osimertinib — and from which countries?
Flow of Osimertinib exports from India: each country's share and the named importers behind the numbers
Osimertinib — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Top 5 importing countries account for 98.2% of global Osimertinib imports — led by Brazil (56.9%) with a total trade value of $1.1M across 130 shipments from India.
Market Analysis: Top Importing Countries & Their Importers
1Brazil
Brazil emerges as the first largest importing country, achieving a total trade value of $620.3K through 44 shipments. This represents a market share of 56.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Brazil has a diverse importer base, with their top importers including:
• TO THE CONCERN PERSON - $125.4K (20.2% of country's total business)
• CONCERN PERSON WANILDA DE - $34.7K (5.6% of country's total business)
• TO THE - $17.2K (2.8% of country's total business)
• GUILHERME MARTINS DE ALMEIDA - $17.1K (2.8% of country's total business)
• TO THE, - $15.4K (2.5% of country's total business)
• Rest of Brazil's importers - $410.6K (66.2% of country's total business)
Key Insight: Brazil demonstrates strong market positioning with an average shipment value of $14.1K, indicating premium pricing strategy compared to the market average of $8.4K.
Brazil is a key market for Osimertinib imports, representing 56.9% of total trade value.
The importation of Osimertinib from India involves various buyer segments, each with distinct purchasing behaviors:
Hospital Groups: Entities like the Indira Gandhi Memorial Hospital in the Maldives fall into this category. They procure Osimertinib directly to meet patient needs, often placing orders based on current demand and treatment protocols. Their purchasing patterns are typically consistent, aligning with patient intake and treatment schedules.
Distributors: Buyers such as "To the Concern Person" in Brazil and Incepta Pharmaceuticals Ltd in Bangladesh act as intermediaries, supplying Osimertinib to healthcare providers and pharmacies. They tend to place larger, periodic orders to maintain inventory levels and meet market demand.
Individual Buyers: Several Brazilian buyers, including "Concern Person Wanilda De," "To The," and "Guilherme Martins De Almeida," appear to be individual purchasers. Their orders are typically smaller and less frequent, likely driven by personal or immediate community needs.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to effectively meet the diverse demands of each buyer type.
Importing Osimertinib into the top five countries involves navigating specific regulatory frameworks:
Brazil:
Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
Import Registration Process: Requires submission of a comprehensive dossier, including clinical data and manufacturing details, followed by ANVISA's evaluation and approval.
Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and ANVISA's review workload.
Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to a standard import duty, which may vary based on trade agreements and specific product classifications.
United Kingdom:
Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
The demand for Osimertinib in importing countries is influenced by several key factors:
Disease Prevalence: Osimertinib is primarily used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations. The prevalence of NSCLC in countries like Brazil and the United Kingdom drives the need for effective treatments, thereby increasing demand for Osimertinib.
Government Healthcare Programs: Initiatives aimed at improving cancer care, such as Brazil's National Cancer Institute (INCA) programs and the UK's National Health Service (NHS) cancer treatment protocols, facilitate access to advanced therapies like Osimertinib.
Universal Health Coverage Expansion: Countries expanding their health coverage, including the Maldives and Bangladesh, are incorporating more comprehensive cancer treatments into their healthcare systems, leading to increased procurement of medications like Osimertinib.
WHO Essential Medicines List Procurement: Inclusion of cancer treatments in the WHO Essential Medicines List encourages countries to procure these medications to meet international healthcare standards.
Common Questions — Osimertinib Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest osimertinib buyer importing from India?
Based on import volume and value, INDIRA GANDHI MEMORIAL HOSPITAL (MALDIVES) leads with $130.8K in imports and a 12.0% market share — the highest of any single osimertinib importer. TO THE CONCERN PERSON (BRAZIL) and INCEPTA PHARMACEUTICALS LTD (BANGLADESH) are the next largest buyers.
QHow many companies buy osimertinib from India?
There are 50 active osimertinib buyers importing from India, with a combined market of $1.1M across 130 shipments to 8 countries. The top 5 buyers hold 31.6% of total import value, while the remaining 45 buyers handle the other 68.4%.
QWhich countries import the most osimertinib from India?
The top importing countries for osimertinib from India are Brazil (56.9%), United Kingdom (24.2%), Maldives (12.0%), Bangladesh (3.3%), Lebanon (1.7%). These markets represent the largest demand centres for Indian pharmaceutical exports of osimertinib, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for osimertinib from India?
The average import transaction value for osimertinib from India is , with an average unit price of . Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
The importation of Osimertinib from India involves various buyer segments, each with distinct purchasing behaviors:
Hospital Groups: Entities like the Indira Gandhi Memorial Hospital in the Maldives fall into this category. They procure Osimertinib directly to meet patient needs, often placing orders based on current demand and treatment protocols. Their purchasing patterns are typically consistent, aligning with patient intake and treatment schedules.
Distributors: Buyers such as "To the Concern Person" in Brazil and Incepta Pharmaceuticals Ltd in Bangladesh act as intermediaries, supplying Osimertinib to healthcare providers and pharmacies. They tend to place larger, periodic orders to maintain inventory levels and meet market demand.
Individual Buyers: Several Brazilian buyers, including "Concern Person Wanilda De," "To The," and "Guilherme Martins De Almeida," appear to be individual purchasers. Their orders are typically smaller and less frequent, likely driven by personal or immediate community needs.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to effectively meet the diverse demands of each buyer type.
Importing Osimertinib into the top five countries involves navigating specific regulatory frameworks:
Brazil:
Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).
Import Registration Process: Requires submission of a comprehensive dossier, including clinical data and manufacturing details, followed by ANVISA's evaluation and approval.
Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and ANVISA's review workload.
Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to a standard import duty, which may vary based on trade agreements and specific product classifications.
United Kingdom:
Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
The demand for Osimertinib in importing countries is influenced by several key factors:
Disease Prevalence: Osimertinib is primarily used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations. The prevalence of NSCLC in countries like Brazil and the United Kingdom drives the need for effective treatments, thereby increasing demand for Osimertinib.
Government Healthcare Programs: Initiatives aimed at improving cancer care, such as Brazil's National Cancer Institute (INCA) programs and the UK's National Health Service (NHS) cancer treatment protocols, facilitate access to advanced therapies like Osimertinib.
Universal Health Coverage Expansion: Countries expanding their health coverage, including the Maldives and Bangladesh, are incorporating more comprehensive cancer treatments into their healthcare systems, leading to increased procurement of medications like Osimertinib.
WHO Essential Medicines List Procurement: Inclusion of cancer treatments in the WHO Essential Medicines List encourages countries to procure these medications to meet international healthcare standards.
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
2United Kingdom
United Kingdom emerges as the second largest importing country, achieving a total trade value of $264.1K through 0 shipments. This represents a market share of 24.2% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: United Kingdom demonstrates strong market positioning with an average shipment value of $264.1K, indicating premium pricing strategy compared to the market average of $8.4K.
United Kingdom is a key market for Osimertinib imports, representing 24.2% of total trade value.
Primary Market
Secondary Market
3Maldives
Maldives emerges as the third largest importing country, achieving a total trade value of $130.8K through 4 shipments. This represents a market share of 12.0% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Maldives has a diverse importer base, with their top importers including:
• INDIRA GANDHI MEMORIAL HOSPITAL - $130.8K (100.0% of country's total business)
Key Insight: Maldives demonstrates strong market positioning with an average shipment value of $32.7K, indicating premium pricing strategy compared to the market average of $8.4K.
Maldives is a key market for Osimertinib imports, representing 12.0% of total trade value.
Primary Market
Secondary Market
4Bangladesh
Bangladesh emerges as the fourth largest importing country, achieving a total trade value of $36.4K through 2 shipments. This represents a market share of 3.3% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Bangladesh has a diverse importer base, with their top importers including:
• INCEPTA PHARMACEUTICALS LTD - $36.4K (100.0% of country's total business)
Key Insight: Bangladesh demonstrates strong market positioning with an average shipment value of $18.2K, indicating premium pricing strategy compared to the market average of $8.4K.
Bangladesh is a key market for Osimertinib imports, representing 3.3% of total trade value.
Primary Market
Secondary Market
5Lebanon
Lebanon emerges as the fifth largest importing country, achieving a total trade value of $18.6K through 0 shipments. This represents a market share of 1.7% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Lebanon demonstrates strong market positioning with an average shipment value of $18.6K, indicating premium pricing strategy compared to the market average of $8.4K.
Lebanon is a key market for Osimertinib imports, representing 1.7% of total trade value.
Primary Market
Secondary Market
TransData Nexus Research · Government and regulatory sources
Mar 2026
Import Registration Process: Requires a Marketing Authorization (MA), involving submission of quality, safety, and efficacy data.
Estimated Timeline: Typically 6 to 12 months, subject to the complexity of the application and MHRA's assessment process.
Import Tariff/Duty: Medicaments under HS Code 30049099 are generally subject to the UK's standard import duties, with specific rates depending on trade agreements and product specifics.
Maldives:
Regulatory Authority: Maldives Food and Drug Authority (MFDA).
Import Registration Process: Involves submission of product dossiers, including manufacturing and clinical data, for MFDA's evaluation.
Estimated Timeline: Approximately 3 to 6 months, depending on the completeness of the submission and MFDA's review process.
Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 may be subject to import duties, with rates determined by Maldivian customs regulations.
Bangladesh:
Regulatory Authority: Directorate General of Drug Administration (DGDA).
Import Registration Process: Requires submission of detailed product information, including quality and clinical data, for DGDA's approval.
Estimated Timeline: Typically 6 to 9 months, contingent on the thoroughness of the application and DGDA's review schedule.
Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 are subject to import duties as per Bangladesh's customs tariff, with rates varying based on product classification and trade agreements.
Lebanon:
Regulatory Authority: Ministry of Public Health (MOPH).
Import Registration Process: Involves submission of a comprehensive dossier, including manufacturing and clinical data, for MOPH's evaluation and approval.
Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and MOPH's review process.
Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to import duties as per Lebanon's customs regulations, with rates varying based on product specifics and trade agreements.
Navigating these regulatory landscapes requires thorough preparation and adherence to each country's specific requirements to ensure successful market entry.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, allowing for bulk purchasing of medications like Osimertinib, which can lead to cost reductions and increased accessibility.
With 50 buyers across 8 countries, the market for Osimertinib imported from India demonstrates a diverse and growing demand, driven by the need for effective cancer treatments and the expansion of healthcare services.
TransData Nexus Research · Government and regulatory sourcesMar 2026
$8.4K
$2290.13 per unit
TransData Nexus Research · Government and regulatory sources
Mar 2026
Import Registration Process: Requires a Marketing Authorization (MA), involving submission of quality, safety, and efficacy data.
Estimated Timeline: Typically 6 to 12 months, subject to the complexity of the application and MHRA's assessment process.
Import Tariff/Duty: Medicaments under HS Code 30049099 are generally subject to the UK's standard import duties, with specific rates depending on trade agreements and product specifics.
Maldives:
Regulatory Authority: Maldives Food and Drug Authority (MFDA).
Import Registration Process: Involves submission of product dossiers, including manufacturing and clinical data, for MFDA's evaluation.
Estimated Timeline: Approximately 3 to 6 months, depending on the completeness of the submission and MFDA's review process.
Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 may be subject to import duties, with rates determined by Maldivian customs regulations.
Bangladesh:
Regulatory Authority: Directorate General of Drug Administration (DGDA).
Import Registration Process: Requires submission of detailed product information, including quality and clinical data, for DGDA's approval.
Estimated Timeline: Typically 6 to 9 months, contingent on the thoroughness of the application and DGDA's review schedule.
Import Tariff/Duty: Pharmaceuticals under HS Code 30049099 are subject to import duties as per Bangladesh's customs tariff, with rates varying based on product classification and trade agreements.
Lebanon:
Regulatory Authority: Ministry of Public Health (MOPH).
Import Registration Process: Involves submission of a comprehensive dossier, including manufacturing and clinical data, for MOPH's evaluation and approval.
Estimated Timeline: Approximately 6 to 12 months, depending on the completeness of the application and MOPH's review process.
Import Tariff/Duty: Pharmaceutical products under HS Code 30049099 are subject to import duties as per Lebanon's customs regulations, with rates varying based on product specifics and trade agreements.
Navigating these regulatory landscapes requires thorough preparation and adherence to each country's specific requirements to ensure successful market entry.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Tender-Based Purchasing: Many countries utilize tender systems for pharmaceutical procurement, allowing for bulk purchasing of medications like Osimertinib, which can lead to cost reductions and increased accessibility.
With 50 buyers across 8 countries, the market for Osimertinib imported from India demonstrates a diverse and growing demand, driven by the need for effective cancer treatments and the expansion of healthcare services.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Analysis Methodology
1.Buyer Identification: 50 global importers of Osimertinib identified from consignee fields in DGFT shipping bill records.
2.Import Value Analysis: Total import value aggregated from 130 individual shipping bill records. Values are FOB in USD.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
4.Geographic Distribution: Buyer imports distributed across 8 destination countries with market share per buyer calculated from capped values.
